False Positive Rate of Cologuard
The false positive rate of Cologuard (multitarget stool DNA test) is approximately 13%, with specificity of 87% for all colorectal lesions and 89.8% for patients with completely negative colonoscopy findings. 1, 2
Quantifying the False Positive Rate
The pivotal FDA approval trial of 9,989 participants established the core performance characteristics:
- Overall specificity: 87% among participants with nonadvanced or negative findings, translating to a 13% false positive rate 2
- Specificity: 89.8% among those with completely negative colonoscopy results, yielding a 10.2% false positive rate in truly disease-free individuals 2
- For comparison, FIT demonstrated superior specificity of 94.9-96.4% in the same populations 2
Real-World Clinical Experience
Recent community-based practice data confirms these rates translate to substantial clinical burden:
- In a 2025 study of 3,119 completed tests, 73% of patients with positive Cologuard results who underwent follow-up colonoscopy had neither cancer nor advanced adenomas 3
- Among 482 positive tests, only 10 patients (4%) had colorectal cancer and 61 (24%) had advanced adenomas, meaning the majority were false positives 3
- The 2023 APAGE-APSDE guidelines explicitly note that "because of the reduced specificity in the pivotal study, there will be some false positives" 1
Clinical Implications of False Positives
The false positive results create a significant colonoscopy burden:
- The USPSTF 2021 guidelines estimate approximately 850 more subsequent follow-up and surveillance colonoscopies needed per 1,000 adults screened with Cologuard compared to other strategies 4
- Each follow-up colonoscopy carries risks: 17.5 serious bleeding events and 5.4 perforations per 10,000 procedures 4
Management of Apparent False Positives
When Cologuard is positive but colonoscopy is negative, repeat Cologuard testing may identify missed lesions:
- In a 2018 study, 5 of 12 patients with persistently positive repeat Cologuard testing had significant findings on repeat colonoscopy, including a 3-cm adenoma with high-grade dysplasia 5
- This corresponded to a positive predictive value of 0.60 for the second Cologuard test 5
- High-quality colonoscopy with careful attention to the right colon is critically important to avoid false negative colonoscopy after positive Cologuard 5
Endoscopist Quality Impact
The false positive rate varies significantly based on endoscopist quality:
- Among endoscopists in the highest adenoma detection rate (ADR) quartile, only 37% of FIT-positive and 37% of Cologuard-positive colonoscopies were negative 6
- This suggests that many "false positives" may actually represent missed lesions by lower-quality endoscopists 6
- A benchmark target of at least 40% ADR is recommended for colonoscopies following positive Cologuard 6
Long-Term Outcomes
False positive Cologuard results do not indicate increased long-term cancer risk:
- A 2017 study with median 4-year follow-up found that aerodigestive cancer incidence in false positive patients did not exceed general population expectations 7
- The US Multi-Society Task Force recommends that patients with negative high-quality colonoscopy should not undergo further upper GI evaluation in the absence of symptoms 1